A year has passed since the Ministry of Health, Labor and Welfare (MHLW) announced its package strategy to fuel the early commercialization of software as a medical device (SaMD) in November last year. A growing number of drug makers are…
ORGANIZATION
PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
PhRMA is still considering its position on a proposal made by the Institute for New Era Strategy (INES) on the Japanese drug pricing system, but is clearly opposing any “cherry picking” by the government, cautioning against the introduction of only…
To read the full story
ORGANIZATION
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
- JPMA Director Gets Sarcastic on MOF’s Data Presentation on Drug Costs
November 19, 2021
- Sales Reps in Japan Log Record Decline in FY2020, Down for 7 Consecutive Years
November 17, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- JPWA Vows to Boost Compliance after New Bid-Rigging Probe
November 12, 2021
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…